Moving Beyond Directly Observed Therapy for Tuberculosis

John Z Metcalfe¹, Max R O'Donnell², David R Bangsberg³

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
² Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, United States of America.
³ Massachusetts General Hospital, Harvard Medical School, Harvard School of Public Health, Boston, Massachusetts, United States of America; Mbarara University of Science and Technology, Mbarara, Uganda.

PMID: 26372602
PMCID: PMC4570797
DOI: 10.1371/journal.pmed.1001877

Moving Beyond Directly Observed Therapy for Tuberculosis

John Z Metcalfe et al. PLoS Med. 2015.

. 2015 Sep 15;12(9):e1001877.

doi: 10.1371/journal.pmed.1001877. eCollection 2015 Sep.

Authors

John Z Metcalfe¹, Max R O'Donnell², David R Bangsberg³

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
² Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, United States of America.
³ Massachusetts General Hospital, Harvard Medical School, Harvard School of Public Health, Boston, Massachusetts, United States of America; Mbarara University of Science and Technology, Mbarara, Uganda.

PMID: 26372602
PMCID: PMC4570797
DOI: 10.1371/journal.pmed.1001877

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Cited by

Tuberculosis therapy in Mumbai: Critical importance of drug-susceptibility testing.
Daftary A, Pai M. Daftary A, et al. Lung India. 2016 May-Jun;33(3):251-2. doi: 10.4103/0970-2113.180799. Lung India. 2016. PMID: 27185986 Free PMC article. No abstract available.
Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, Khaparde SD. Parmar MM, et al. PLoS One. 2018 Apr 11;13(4):e0193903. doi: 10.1371/journal.pone.0193903. eCollection 2018. PLoS One. 2018. PMID: 29641576 Free PMC article.
Effectiveness of a mobile health application on treatment outcomes among patients with tuberculosis in Shanghai, China: a multicentre randomised controlled trial.
Qin N, Chen J, Chen L, Hu W, Feng Y, Xu C, Zhang H, Hou Y, Tang L, Shen X, Wu Z. Qin N, et al. BMJ Glob Health. 2025 Jun 6;10(6):e018022. doi: 10.1136/bmjgh-2024-018022. BMJ Glob Health. 2025. PMID: 40480646 Free PMC article. Clinical Trial.
Acceptability, feasibility, and impact of a pilot tuberculosis literacy and treatment counselling intervention: a mixed methods study.
Law S, Seepamore B, Oxlade O, Sikhakhane N, Dawood H, Chetty S, Padayatchi N, Menzies D, Daftary A. Law S, et al. BMC Infect Dis. 2021 May 18;21(1):449. doi: 10.1186/s12879-021-06136-1. BMC Infect Dis. 2021. PMID: 34006254 Free PMC article.
Integrating services for HIV and multidrug-resistant tuberculosis: A global cross-sectional survey among ART clinics in low- and middle-income countries.
Zürcher K, Cox SR, Ballif M, Enane LA, Marcy O, Yotebieng M, Reubenson G, Imsanguan W, Otero L, Suryavanshi N, Duda SN, Egger M, Tornheim JA, Fenner L; International Epidemiology Databases to Evaluate AIDS (IeDEA). Zürcher K, et al. PLOS Glob Public Health. 2022;2(3):e0000180. doi: 10.1371/journal.pgph.0000180. Epub 2022 Mar 1. PLOS Glob Public Health. 2022. PMID: 36778080 Free PMC article.

See all "Cited by" articles

References

1. Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN, et al. The Emergence of Isoniazid-Resistant Cultures in Patients with Pulmonary Tuberculosis during Treatment with Isoniazid Alone or Isoniazid Plus Pas. Bull World Health Organ. 1964;31:273–94. - PMC - PubMed
1. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. American review of tuberculosis. 1952;65(5):523–46. - PubMed
1. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med. 1970;283(12):616–21. - PubMed
1. Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I. Linezolid for XDR-TB—Final Study Outcomes. N Engl J Med. 2015;373(3):290–1. 10.1056/NEJMc1500286 - DOI - PMC - PubMed
1. Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. Int J Tuberc Lung Dis. 1999;3(1):1–3. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Moving Beyond Directly Observed Therapy for Tuberculosis

Affiliations

Moving Beyond Directly Observed Therapy for Tuberculosis

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical